In Vitro Demonstration of Direct Platelet-Related Effects of PCSK9 Enzyme

November 4, 2024 updated by: Paul A. Gurbel, LifeBridge Health

Evaluation of PCSK9 Enzyme in Non-Cholesterol Biological Pathways: In Vitro Demonstration of Direct Platelet-Related Effects of PCSK9 Enzyme

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in lipid metabolism and therapeutic target for hypercholesterolemia and atherosclerotic cardiovascular disease (CVD). Furthermore, research from in-vitro and in-vivo animal models suggest that the inhibition of PCSK9 expression may suppress platelet activation, and systemic inflammation thereby reducing thrombotic risk. Taken together, these data support the lower rates of myocardial infarction, stroke, and coronary revascularization in subjects with increased CVD risk in clinical trials with alirocumab (Praluent) and evolocumab (Repatha) as compared to placebo. The main aim of this single center, exploratory in-vitro evaluation is to investigate the direct role of PCSK9 on platelet activation and aggregation using blood collected from a diverse population of antiplatelet naïve healthy volunteers (n=40) and subjects with CVD risk factors (n=40) between the 18-50 years of age. All procedures including consenting, collection of clinical data, and lab processing will occur at the Sinai Center for Thrombosis Research. The results of this study will provide a better understanding of cardioprotective effects of PCSK9 inhibition beyond lipid lowering.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

The pivotal role of platelets during arterial ischemic events, such as myocardial infarction (MI), stroke, and cardiovascular (CV) death, and the significant role of potent antiplatelet therapy in reducing these events have been well defined. An independent association between plasma PCSK9 levels, elevated platelet reactivity, and ischemic outcomes in patients with acute coronary syndromes (ACS) has been demonstrated. The association of plasma PCSK9 levels with coronary artery disease (CAD) risk, independent of low-density lipoprotein cholesterol (LDL-C) levels, has been suggested. Based on a meta-analysis of trials of medium-high risk cardiovascular disease (CVD) patients, the investigators have demonstrated a significant mortality and MI reduction with PCSK9 antibodies and suggested a relevant ant ischemic/antiplatelet role of PCSK9 antibodies. These observations support the hypothesis that the anti-ischemic effects of PCSK9 inhibitor therapy are related to its pleiotropic effects on platelets.

In vitro, animal, and human studies have suggested the direct effects of PCSK9 and PCSK9 inhibitors on platelets. PCSK9 indirectly activates platelets through elevated LDL-C and oxLDL levels. oxLDL can activate platelets by binding to the scavenger receptors CD36 and LOX-1. In addition, a direct relationship between PCSK9 and platelet activation through the scavenger receptors CD36 and Lectin-like oxidized LDL receptor (LOX)-1 has been suggested. Incubation of human recombinant PCSK9 protein with platelet-rich plasma collected from healthy subjects significantly enhanced activated GPIIb/IIIa receptor expression and platelet aggregation induced by suboptimal concentrations of epinephrine. In in vitro experiments, human recombinant PCSK9 exposure enhanced LOX-1 expression in human vascular endothelial cells and smooth muscle cells. Similarly, LOX-1 KO mice showed lower PCSK9 levels and PCSK9-KO mice showed much lower LOX-1 levels, indicating a reciprocal relationship between PCSK9 and LOX-1. A similar reciprocal relationship between PCSK9 levels and LOX-1 and CD36 expression has not been demonstrated in human platelets.

In vitro immunoblotting experiments demonstrated the presence of PCSK9 in platelets obtained from patients with CAD, and flow cytometry experiments demonstrated that collagen-related peptide (CP) significantly enhanced the surface expression of PCSK9 on platelets. Furthermore, PCSK9 antibodies significantly inhibited ADP- and CP-induced platelet aggregation and platelet-dependent thrombus formation on the immobilized collagen surface under high shear rate (1000s-1). Binding of PCSK9 to CD36 triggers platelet activation through activation of nicotinamide adenine dinucleotide phosphate oxidase (Nox)2, release of reactive oxygen species (ROS), and subsequent activation of GPIIb/IIIa receptor and p-selectin release. In addition, Nox2 induces the generation of 8-Iso-prostaglandin F2α and thromboxane (Tx) A2 through the activation f cytosolic phospholipase A2 and finally results in the activation of the GP-IIb/IIIa receptor and p-selectin release. The relationship between plasma PCSK9, urinary 11-dehydro-TxB2, and CV events in patients with atrial fibrillation has been demonstrated. Furthermore, washed platelets resuspended in plasma from patients with familial hypercholesterolemia after PCSK9 inhibitor treatment induced lower platelet aggregation and soluble Nox2-derived peptide (sNox2-dp) release than those obtained using plasma before PCSK9 inhibitor treatment in an in vitro study. This reduction was reversed by the addition of oxLDL. Furthermore, oxLDL-induced platelet aggregation was reduced by inhibiting CD36, LOX-1, and Nox2. In the same study, 6-month treatment with PCSK9 inhibitors was shown to reduce serum LDL-C, oxLDL, serum TxB2, sNox2-dp, and PCSK9 levels.

These preliminary observations suggest that:

  • CV benefits associated with PCSK9 inhibitor therapy may be in part related to its pleiotropic effects on platelets.
  • In vitro, animal, and clinical studies suggested direct effects of PCSK9 on platelets.
  • PCSK9 influence platelet function through CD36/LOX-1 receptor mediated Nox2 activity.

However, the potential direct platelet effects of PCSK9 on platelets have not been demonstrated in a comprehensive study involving a diverse population of healthy volunteers and subjects with cardiovascular risk factors. Inclusion of at least 3 CV risk factors will increase the chance of finding subjects with an elevated platelet reactivity phenotype and demonstration of enhanced platelet-related effect of PCSK9. The presence of these risk factors has been traditionally attributed to increased prevalence of CVD and associated risk.

In contemporary CV clinical trials, a very low percentage (<10%) of African Americans are represented despite a more pronounced CVD risk. Furthermore, it has been demonstrated that PCSK9 levels are significantly higher in African Americans vs Caucasians (104 ± 29 vs 95 ± 30 ng/mL, respectively; P = 0.020). At Sinai Hospital of Baltimore, the investigators have reported higher rates of post-PCI ischemic events and greater mortality in African Americans than in Whites. Rare loss-of-function (LoF) mutations of PCSK9 have been associated with low levels of LDL-C (28% lower in Blacks and 15% in Whites) and with an even more impressive reduction in the risk of coronary artery disease (CAD) (88% and 47%, respectively). PCSK9 LoF variants were associated with 35 mg/dL and 13 mg/dL lower LDL-C levels in African Americans and Caucasians, respectively, and a 49% and 18% lower risk for coronary heart disease in African Americans and Caucasians, respectively. In a study of 10,196 US African American adults, PCSK9 LoF variants were associated with lower concentrations of lipoprotein (Lpa) and OxPL-apoB. These data indicate a direct relationship between PCSK9 and the risk of CAD, and the importance of lowering PCSK9 levels in reducing CAD risk among African Americans.

The knowledge gained by our exploratory mechanistic study will help us to understand the direct effects of PCSK9 and PCSK9 inhibitor on platelets and facilitate the clinical application of PCSK9 inhibitors in a broad range of patients with cardiovascular risk.

Study Type

Observational

Enrollment (Estimated)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

This trial has been designed to ensure enrollment of healthy volunteers and subjects with CV risk to allow for comparisons across disease states in order to fulfill study objectives. Compared to healthy volunteers, subjects with CV risk factors are highly prothrombotic and exhibit a high platelet reactivity phenotype. Coexistence of at least three risk factors indicate a high risk for future CV events. African Americans and women are inherently at elevated risk for CVD, associated ischemic events, and exhibit higher serum PCSK9 levels. Therefore, equal inclusion of race and genders should provide robust variability in PCSK9 levels for evaluation of platelet related effects of PCSK9.

Description

Inclusion Criteria:

  • Healthy subjects (n=40): 18-50 years old male and female subjects without any conditions or taking any agents or food supplements that may influence platelet function as determined by the study principal investigator.
  • Subjects with CV risk factors (n=40): 18-50 years old male and female subjects with at least three of the following CV risk factors:

History of hypercholesterolemia, hypertension, overweight, current smoker, prediabetes or diabetes who are only on metformin and insulin, and family history of coronary artery, peripheral artery, or cerebrovascular disease.

Overweight is defined as subjects with BMI ≥25 kg/m2 (https://www.heart.org/en/healthy-living/healthy-eating/losing-weight/bmi-in-adults).

Diabetes is defined as haemoglobin (Hb)A1c ≥6.5%, prediabetes =5.7%-6.4%) (https://diabetes.org/about-diabetes/diagnosis)

Exclusion Criteria:

  • Subjects with Diabetes mellitus, who are on GLP-1 agonists or SGLT2 inhibitors.
  • Subjects on high dose statin therapy or PCSK9 therapy.
  • Prior coronary of cerebrovascular event requiring intervention.
  • Use of any antiplatelet or anticoagulant therapy within 14 days of enrollment.
  • Subjects with a history of chronic kidney disease, liver disease, pancreatitis, HIV, hepatitis, and active cancer, active infection, or any other medical condition or concomitant medications as determined by the investigator that may affect study results.
  • Pregnant

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Healthy
Participants (approximately 40) 18-50 years old male and female without any major medical conditions or taking any agents or food supplements that may influence platelet function as determined by the study principal investigator.
Drug: PCSK9 Antibody, PCSK9 Enzyme
In-vitro demonstration of the direct effect if the PCSK9 enzyme on platelets. The study will use commercially available recombinant PCSK9 enzyme to promote platelet activity and the PCSK9 antibody to inhibit activity. In each patient, platelet function testing will occur in the absence of PCSK9 enzyme, after the addition of PCSK9 enzyme, and after the addition of both PCSK9 enzyme and antibody reagent to the blood sample prior to testing.
Cardiovascular Risk Factor
Participants (approximately 40) 18-50 years old male and female with at least three of the following risk factors: history of hypercholesterolemia, hypertension, overweight, current smoker, prediabetes or diabetes who are only on metformin and insulin, and a family history of coronary artery, peripheral artery, or cerebrovascular disease.
Drug: PCSK9 Antibody, PCSK9 Enzyme
In-vitro demonstration of the direct effect if the PCSK9 enzyme on platelets. The study will use commercially available recombinant PCSK9 enzyme to promote platelet activity and the PCSK9 antibody to inhibit activity. In each patient, platelet function testing will occur in the absence of PCSK9 enzyme, after the addition of PCSK9 enzyme, and after the addition of both PCSK9 enzyme and antibody reagent to the blood sample prior to testing.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference in ADP-induced platelet aggregation (%) with and without PCSK9 enzyme
Time Frame: Throughout study completion, an average of about 1 year
Difference in ADP-induced platelet aggregation (%) with and without addition of PCSK9 enzyme in blood collected from healthy volunteers and subjects with cardiovascular risk factors.
Throughout study completion, an average of about 1 year
Difference in collagen related peptide -induced platelet aggregation (%) with and without PCSK9 enzyme
Time Frame: Throughout study completion, an average of about 1 year
Difference in collagen related peptide-induced platelet aggregation (%) with and without PCSK9 enzyme in blood collected from healthy volunteers and subjects with cardiovascular risk factors.
Throughout study completion, an average of about 1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference in ADP-induced platelet aggregation (%) with PCSK9 enzyme alone and with addition of PCSK9 antibody
Time Frame: Throughout study completion, an average of about 1 year
Difference in ADP-induced platelet aggregation (%) with PCSK9 enzyme alone and after addition of PCSK9 antibody in blood collected from healthy volunteers and subjects with cardiovascular risk factors
Throughout study completion, an average of about 1 year
Difference in collagen related peptide-induced platelet aggregation (%) with PCSK9 enzyme alone and with addition of PCSK9 antibody
Time Frame: Throughout study completion, an average of about 1 year
Difference in collagen related peptide-induced platelet aggregation (%) with PCSK9 enzyme alone and with addition of PCSK9 antibody in blood collected from healthy volunteers and subjects with cardiovascular risk factors.
Throughout study completion, an average of about 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

LifeBridge Health

Collaborators

Merck Sharp & Dohme LLC

Investigators

  • Principal Investigator: Paul Gurbel, MD, FACC, LifeBridge Health

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2024

Primary Completion (Estimated)

December 1, 2025

Study Completion (Estimated)

December 30, 2025

Study Registration Dates

First Submitted

November 1, 2024

First Submitted That Met QC Criteria

November 4, 2024

First Posted (Actual)

November 6, 2024

Study Record Updates

Last Update Posted (Actual)

November 6, 2024

Last Update Submitted That Met QC Criteria

November 4, 2024

Last Verified

November 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2253810

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

This is an exploratory in-vitro study not involving clinical outcome endpoints and may not necessitate sharing individual data. A decision will be made after the study is underway.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypertension

Clinical Trials on PCSK9 Antibody, PCSK9 Enzyme

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe